
Exact Sciences (EXAS) Stock Forecast & Price Target
Exact Sciences (EXAS) Analyst Ratings
Bulls say
Exact Sciences has demonstrated a strong growth trajectory with its Cologuard product, achieving approximately 14% growth in Q1'25, driven by increased re-screening, care gap programs, and new ordering providers, which has contributed to an upward revision of the fiscal year 2025 revenue guidance. The launch of Cologuard Plus has also seen early success, with test volumes exceeding 30,000, prompting a significant year-over-year increase of over 20% in sales and marketing spending to accelerate adoption further. Additionally, upcoming pipeline developments, such as the BLUE-C readout and the CancerGuard launch, are anticipated to provide further growth catalysts throughout the year.
Bears say
Exact Sciences is facing significant challenges that contribute to a negative outlook on its stock. The company’s anticipated product launches are crucial to maintaining growth, yet there are concerns that these launches may not materialize as expected, potentially relegating Exact to a lower growth comparison group. Additionally, the recent launch of the Oncodetect test has not been included in the company's fiscal guidance for FY'25 and is projected to negatively impact gross margins in the latter half of that year.
This aggregate rating is based on analysts' research of Exact Sciences and is not a guaranteed prediction by Public.com or investment advice.
Exact Sciences (EXAS) Analyst Forecast & Price Prediction
Start investing in Exact Sciences (EXAS)
Order type
Buy in
Order amount
Est. shares
0 shares